Cargando…
The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy
Radiation therapy is potentially immunogenic yet it rarely generates long-term antitumor effects. We have recently demonstrated that Toll-like receptor 9 (TLR9) jump-starts the signal transduction and activator of transcription 3 (STAT3)-dependent vascularization and regrowth of tumors that recur up...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Landes Bioscience
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203530/ https://www.ncbi.nlm.nih.gov/pubmed/25340001 http://dx.doi.org/10.4161/onci.27894 |